Skip to main content

Table 3 Disproportionality analysis

From: Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting

Oral

Subcutaneous

PTs

N(%)

ROR (95%CI)

PTs

N(%)

ROR (95%CI)

Vision blurred

69(34.33)

4.15(3.27–5.25)

Vision blurred

433(26.84)

2.58(2.35–2.84)

Visual impairment

38(18.91)

2.45(1.78–3.37)

Visual impairment

392(24.30)

2.51(2.27–2.78)

Blindness

10(4.98)

2.03(1.09–3.78)

Cataract

98(6.08)

1.37(1.12–1.67)

Diabetic retinopathy

8(3.98)

18.99(9.49–38.02)

Diabetic retinopathy

76(4.71)

18.31(14.58–23.00)

Eye haemorrhage

6(2.99)

3.55(1.60–7.92)

Blindness

69(4.28)

1.39(1.10–1.76)

Dry eye

6(2.99)

1.12(0.50–2.50)

Retinopathy

56(3.47)

11.93(9.16–15.54)

Blindness unilateral

5(2.49)

2.88(1.20–6.93)

Eye pain

37(2.29)

0.57(0.41–0.79)

Eye pain

5(2.49)

0.78(0.32–1.86)

Diplopia

36(2.23)

1.12(0.81–1.55)

Cataract

5(2.49)

0.70(0.29–1.69)

Dry eye

36(2.23)

0.67(0.48–0.93)

Diplopia

4(2.00)

1.25(0.47–3.33)

Eye haemorrhage

31(1.92)

1.83(1.28–2.60)

Vitreous haemorrhage

4(2.00)

11.70(4.39–31.21)

Blindness unilateral

30(1.86)

1.72(1.20–2.46)

Eye swelling

4(2.00)

0.88(0.33–2.35)

Ischemic neuropathy

30(1.86)

9.15(6.38–13.12)

Visual acuity reduced

3(1.49)

0.67(0.22–2.09)

Eye disorder

27(1.67)

0.67(0.46–0.98)

Ocular hyperaemia

3(1.49)

0.55(0.18–1.70)

Vitreous floaters

23(1.43)

1.95(1.29–2.93)

Vitreous floaters

3(1.49)

2.56(0.82–7.93)

Retinal detachment

20(1.24)

1.79(1.15–2.77)

Macular degeneration

3(1.49)

2.15(0.69–6.68)

Vitreous haemorrhage

19(1.18)

5.55(3.53–8.71)

Blindness transient

2(1.00)

2.20(0.55–8.79)

Eye pruritus

18(1.12)

0.49(0.31–0.77)

Visual field defect

2(1.00)

1.96(0.49–7.85)

Ocular hyperaemia

17(1.05)

0.31(0.19–0.50)

Glaucoma

2(1.00)

0.84(0.21–3.35)

Photophobia

17(1.05)

0.75(0.47–1.21)

Retinal haemorrhage

2(1.00)

2.26(0.57–9.06)

Eye swelling

17(1.05)

0.37(0.23–0.60)

Photophobia

2(1.00)

0.89(0.22–3.55)

Lacrimation increased

17(1.05)

0.48(0.30–0.77)

Vitreous detachment

2(1.00)

7.63(1.91–30.53)

Glaucoma

16(1.00)

0.67(0.41–1.09)

Retinal tear

2(1.00)

6.77(1.69–27.09)

Eye irritation

15(0.93)

0.24(0.15–0.40)

Eye disorder

2(1.00)

0.50(0.12–2.00)

Macular degeneration

13(0.81)

0.93(0.54–1.60)

Ocular discomfort

2(1.00)

1.70(0.43–6.81)

Retinal tear

13(0.81)

4.39(2.54–7.57)

Lacrimation increased

2(1.00)

0.57(0.14–2.27)

Blindness transient

12(0.74)

1.31(0.74–2.31)

Miosis

2(1.00)

2.11(0.53–8.43)

Retinal haemorrhage

12(0.74)

1.35(0.77–2.38)

Photopsia

1(0.50)

1.27(0.18–8.98)

Ocular discomfort

12(0.74)

1.01(0.58–1.79)

Accommodation disorder

1(0.50)

10.63(1.50–75.60)

Macular oedema

11(0.68)

1.60(0.89–2.90)

Myopia

1(0.50)

3.35(0.47–23.81)

Vitreous detachment

10(0.62)

3.80(2.04–7.07)